Correlation Between Biomarin Pharmaceutical and CytomX Therapeutics

Can any of the company-specific risk be diversified away by investing in both Biomarin Pharmaceutical and CytomX Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Biomarin Pharmaceutical and CytomX Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Biomarin Pharmaceutical and CytomX Therapeutics, you can compare the effects of market volatilities on Biomarin Pharmaceutical and CytomX Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Biomarin Pharmaceutical with a short position of CytomX Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Biomarin Pharmaceutical and CytomX Therapeutics.

Diversification Opportunities for Biomarin Pharmaceutical and CytomX Therapeutics

-0.57

Correlation Coefficient

Biomarin Pharmaceutical  CytomX Therapeutics

Excellent diversification

The 3 months correlation between Biomarin and CytomX is -0.57. Overlapping area represents the amount of risk that can be diversified away by holding Biomarin Pharmaceutical and CytomX Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CytomX Therapeutics and Biomarin Pharmaceutical is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Biomarin Pharmaceutical are associated (or correlated) with CytomX Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CytomX Therapeutics has no effect on the direction of Biomarin Pharmaceutical i.e., Biomarin Pharmaceutical and CytomX Therapeutics go up and down completely randomly.

Pair Corralation between Biomarin Pharmaceutical and CytomX Therapeutics

Given the investment horizon of 90 days Biomarin Pharmaceutical is expected to generate 0.34 times more return on investment than CytomX Therapeutics. However, Biomarin Pharmaceutical is 2.9 times less risky than CytomX Therapeutics. It trades about 0.12 of its potential returns per unit of risk. CytomX Therapeutics is currently generating about -0.15 per unit of risk. If you would invest  6,545  in Biomarin Pharmaceutical on December 29, 2024 and sell it today you would earn a total of  738.00  from holding Biomarin Pharmaceutical or generate 11.28% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Biomarin Pharmaceutical  vs.  CytomX Therapeutics

Biomarin Pharmaceutical

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Biomarin Pharmaceutical are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Biomarin Pharmaceutical may actually be approaching a critical reversion point that can send shares even higher in April 2025.

CytomX Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days CytomX Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's primary indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Biomarin Pharmaceutical and CytomX Therapeutics

The main advantage of trading using opposite Biomarin Pharmaceutical and CytomX Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Biomarin Pharmaceutical position performs unexpectedly, CytomX Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CytomX Therapeutics will offset losses from the drop in CytomX Therapeutics' long position.

The idea behind Biomarin Pharmaceutical and CytomX Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.